Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations

BACKGROUND: Osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), can be used as second-line treatment for lung cancer patients harboring the T790M substitution. Although osimertinib is more effective than the first-generation EGFR-TKIs used for fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Yuichiro, Naka, Go, Yamaguchi, Yoh, Hashimoto, Masao, Suzuki, Manabu, Izumi, Shinyu, Sugiyama, Haruhito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531095/
https://www.ncbi.nlm.nih.gov/pubmed/33008313
http://dx.doi.org/10.1186/s12885-020-07424-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531095/
https://www.ncbi.nlm.nih.gov/pubmed/33008313
http://dx.doi.org/10.1186/s12885-020-07424-w

Ejemplares similares